Skip to main content
Vivo Bio tech Ltd. logo

Vivo Bio tech Ltd. — Investor Relations & Filings

Ticker · 511509 ISIN · INE380K01017 LEI · 98450079E4M2CR80D882 BSE.NS Professional, scientific and technical activities
Open in API
Filings indexed 440 across all filing types
Latest filing 2025-02-21 Capital/Financing Update
Country IN India
Listing BSE.NS 511509

About Vivo Bio tech Ltd.

http://www.vivobio.com/

Vivo Bio Tech Ltd. is a preclinical Contract Research Organization (CRO) providing comprehensive drug discovery and development services. The company specializes in conducting in vivo preclinical studies, including toxicology, pharmacology, and pharmacokinetic evaluations. It operates advanced facilities for the breeding and distribution of Specific Pathogen Free (SPF) laboratory animal models, maintained through strategic partnerships with global leaders like Taconic Biosciences. Vivo Bio Tech offers regulatory-compliant services such as safety assessment, efficacy testing, and specialized research models to support pharmaceutical and biotechnology sectors. Its operations are characterized by adherence to Good Laboratory Practice (GLP) standards and AAALAC accreditation, ensuring high-quality data for global regulatory submissions.

Recent filings

Filing Released Lang Actions
Please find enclosed intimation for allotment of convertible equity warrants.
Capital/Financing Update Classification · 100% confidence The document is a formal communication addressed to the stock exchange (BSE Limited) regarding the allotment of convertible equity warrants. It references compliance with SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, and details the allotment of warrants following a special resolution passed at an Extraordinary General Meeting. The document includes specifics about the number of warrants allotted, the issue price, the category of allottees, and the post-allotment shareholding structure. It also mentions regulatory references such as SEBI Circulars and provides detailed disclosures as required under Regulation 30 of the SEBI Listing Regulations. The content is focused on a capital raising event through preferential allotment of convertible warrants, which is a financing activity. There is no indication that this is a full financial report, audit report, or earnings release. The document is not a mere announcement of a report but a substantive update on a capital/financing transaction. Therefore, the appropriate classification is Capital/Financing Update (CAP).
2025-02-21 English
Please find enclosed intimation for allotment of convertible equity warrants.
Capital/Financing Update Classification · 95% confidence The document is a formal notification addressed to the stock exchange (BSE Limited) regarding the allotment of convertible equity warrants following a special resolution passed at an Extraordinary General Meeting. It references compliance with SEBI Listing Obligations and Disclosure Requirements Regulations, 2015, and SEBI ICDR Regulations, 2018. The content details the number of warrants allotted, the issue price, the allottee, and the post-allotment shareholding structure. There is no financial statement or comprehensive financial analysis present, but rather an update on a capital raising event through preferential allotment of warrants. This fits the definition of a Capital/Financing Update (CAP), which covers updates on company fundraising and capital structure changes. The document length (5828 characters) and detailed disclosure confirm it is not a mere announcement of a report but a substantive update on financing activity.
2025-02-20 English
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Madhavi Latha Kompella
Regulatory Filings
2025-02-20 English
Please find enclosed scrutinizers report
Regulatory Filings
2025-02-07 English
please find enclosed proceedings of EGM
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a detailed summary of the proceedings of an Extra-Ordinary General Meeting (EGM) held on February 7, 2025. It includes information about the meeting's conduct, attendees, agenda items, voting procedures, and compliance with SEBI regulations. The document specifically states it is a "Summary of the Proceedings of Extra-Ordinary General Meeting" and provides details on voting results and regulatory compliance. It is not the actual voting results declaration but a summary of the meeting proceedings. Therefore, the document fits best under the category of Declaration of Voting Results & Voting Rights Announcements (DVA), as it relates to the official disclosure of meeting proceedings and voting processes for shareholder decisions at a general meeting.
2025-02-07 English
please find enclosed outcome of EGM
Regulatory Filings
2025-02-07 English

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.